Pegzilarginase-nbln
Overview
Pegzilarginase-nbln (brand: Loargys) is a PEGylated recombinant human arginase 1 enzyme. It degrades L-arginine to reduce its toxic accumulation in patients with Arginase 1 Deficiency (a rare urea cycle disorder). FDA approved February 23, 2026 for hyperarginemia in patients 2 years and older with Arginase 1 Deficiency, used with dietary protein restriction. Administered by IV infusion.
Protocols & dosing
Detailed dosing protocols have not yet been catalogued.
FDA & legal status
Pegzilarginase-nbln is approved by the U.S. Food and Drug Administration for one or more clinical indications. Refer to the prescribing information for full safety and dosing details.
| Country | Status |
|---|---|
| United States | FDA approved |
| United Kingdom | Prescription-only / not licensed |
| Canada | Prescription-only / Schedule F if licensed |
| Australia | TGA-scheduled |
Vendor information
PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.
References
No external sources have been catalogued for this article yet.
Related peptides
- AOD-9604 — Fat loss, metabolic enhancement
- CagriSema — Combination therapy
- Dulaglutide — Weekly GLP-1 (Trulicity)
- Fragment 176-191 — HGH fragment for fat loss
- Leptin — Satiety hormone
- Liraglutide — FDA-approved GLP-1 for weight loss